Utah Medical Products UTMD
- Market cap
- $224.6M
- PE
- 21.5×
- 10y median 20.9×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 6.2×
- EV/EBIT
- 4.8×
- Revenue, 12 months
- $36.1M
- −7% on a year ago
- Net margin
- 29.0%
- Free cash flow yield
- 5.1%
Utah Medical Products trades at 21.5× trailing earnings, near its ten-year median. Revenue was $36.1M over the last twelve months, down 7% on a year earlier with a 29% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $12.5M−4% | $12.3M−9% | $11.3M−9% | $10.4M−19% | $10M−20% | $9.2M−26% | $9.7M−14% | $10M−4% | $9.8M−2% | $9M−1% | $8.7M−10% | $8.5M−14% | |
| Cost of revenue | $5.1M+8% | $5.2M−0% | $4.6M−2% | $4.1M−19% | $4.2M−18% | $3.8M−27% | $4.2M−9% | $4.4M+5% | $4.2M+0% | $3.8M−1% | $3.4M−18% | $3.8M−14% |
| Gross profit | $7.4M−10% | $7.1M−15% | $6.8M−14% | $6.3M−19% | $5.8M−21% | $5.3M−25% | $5.5M−18% | $5.6M−11% | $5.6M−3% | $5.3M−1% | $5.3M−5% | $4.8M−15% |
| R&D | $138K+23% | $146K+19% | $266K+85% | $255K+92% | $172K+25% | $121K−17% | $154K−42% | $135K−47% | $167K−3% | $212K+75% | $154K+0% | $154K+14% |
| SG&A | $3.3M+11% | $3M−4% | $2.6M−20% | $2.6M−20% | $2.3M−30% | $2.3M−25% | $2.2M−15% | $2.3M−12% | $2.8M+24% | $2.6M+15% | $2.6M+15% | $2M−14% |
| $4M−23% | $3.9M−22% | $3.9M−13% | $3.4M−22% | $3.3M−16% | $2.9M−26% | $3.2M−19% | $3.2M−7% | $2.6M−22% | $2.4M−17% | $2.6M−19% | $2.6M−17% | |
| Pre-tax income | $4.8M−11% | $5M−10% | $4.8M−6% | $4.2M−19% | $4.2M−13% | $3.6M−28% | $3.9M−20% | $3.8M−9% | $3.3M−21% | $3.1M−14% | $3.2M−18% | $3.3M−14% |
| $846K−20% | $731K−29% | $842K−7% | $758K−22% | $616K−27% | $712K−3% | $817K−3% | $788K+4% | $678K+10% | $540K−24% | $578K−29% | $600K−24% | |
| Net income | $3.9M−8% | $4.3M−6% | $4M−6% | $3.5M−18% | $3.6M−10% | $2.9M−32% | $3M−23% | $3M−12% | $2.6M−26% | $2.6M−12% | $2.6M−14% | $2.7M−12% |
| $1.08−9% | $1.18−6% | $1.09−6% | $0.98−15% | $1.02−6% | $0.86−27% | $0.92−16% | $0.94−4% | $0.82−20% | $0.80−7% | $0.82−11% | $0.84−11% | |
| 3.6M+0% | 3.6M+0% | 3.6M−1% | 3.5M−3% | 3.5M−4% | 3.4M−7% | 3.3M−9% | 3.2M−8% | 3.2M−8% | 3.2M−6% | 3.2M−4% | 3.2M−2% |
EPS, diluted: Q4 FY10: quarter's net income to common over its shares, to the cent, the shares from counts implied by EPS, near the year's EPS less the nine months'. 7 periods, Q4 FY11 to Q4 FY17: quarter's net income to common over its shares, to the cent.
Diluted shares: 14 periods, Q4 FY11 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY17: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest Utah Medical Products' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| UTMDUtah Medical Products | $224.6M | 21.5× | 20.9× | 6.2× | −7% | 29.0% | |
| PDEXPro DEX | $184.5M | 15.9× | 16.5× | 2.3× | +13% | 15.1% | |
| INFUInfuSystem | $275.7M | 33.8× | 43.5× | 1.9× | +2% | 6.0% | |
| EMBCEmbecta | $350.7M | 4.2× | 11.6× | 0.3× | −8% | 8.6% | |
| TCMDTactile Systems Technology | $518.1M | 21.2× | 62.3× | 1.5× | +17% | 7.1% | |
| KEQUKewaunee Scientific | $96.7M | 12.1× | 13.6× | 0.3× | +5% | 3.0% | |
| MOVMovado | $710.9M | 17.7× | 13.4× | 1.0× | +5% | 6.0% | |
| APTAlpha Pro Tech | $56.3M | 13.5× | 14.8× | 0.9× | +6% | 6.8% | |
| IRMDIradimed | $1B | 42.5× | 41.5× | 11.4× | +11% | 26.8% | |
| IARTIntegra Lifesciences | $1.1B | 80.1× | 46.3× | 0.6× | +1% | 0.8% | |
| BVSBioventus | $1.1B | 17.1× | 27.1× | 1.9× | +4% | 9.4% | |
| Peer median | $434.4M | 17.4× | 21.8× | 1.3× | +5% | 6.9% |
More on Utah Medical Products
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .